BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

BMT CTN #1503: A Study to Compare Hematopoetic Cell (Bone Marrow) Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease

Sponsor
NMDP

Protocol Number
BMT CTN 1503

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910